Shell Asset Management CO Ultragenyx Pharmaceutical Inc. Transaction History

Shell Asset Management CO

$2.27 Billion
Q3 2024

A detailed history of Shell Asset Management CO transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 2,255 shares of RARE stock, worth $100,911. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,255

Previous 2,386 5.49%

Holding current value

$100,911

Previous $98,000 27.55%

% of portfolio

0.01%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$40.21 - $59.36 $5,267 - $7,776	-131 Reduced 5.49%	2,255 $125,000
Q1 2024 Jul 31, 2024	SELL	$43.02 - $53.69 $6,453 - $8,053	-150 Reduced 5.91%	2,386 $98,000
Q1 2024 May 14, 2024	SELL	$43.02 - $53.69 $4,172 - $5,207	-97 Reduced 3.68%	2,536 $118,000
Q4 2023 Feb 14, 2024	SELL	$31.73 - $49.19 $25,130 - $38,958	-792 Reduced 23.12%	2,633 $126,000
Q3 2023 Nov 08, 2023	SELL	$34.92 - $46.66 $1,885 - $2,519	-54 Reduced 1.55%	3,425 $122,000
Q2 2023 Jul 28, 2023	SELL	$37.35 - $52.15 $747 - $1,043	-20 Reduced 0.57%	3,479 $160,000
Q1 2023 May 15, 2023	SELL	$36.99 - $48.71 $443 - $584	-12 Reduced 0.34%	3,499 $140,000
Q4 2022 Feb 07, 2023	SELL	$33.72 - $46.33 $24,042 - $33,033	-713 Reduced 16.88%	3,511 $163,000
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $44,155 - $73,084	-1,105 Reduced 20.74%	4,224 $175,000
Q2 2022 Aug 09, 2022	BUY	$45.8 - $85.4 $366 - $683	8 Added 0.15%	5,329 $318,000
Q1 2022 May 04, 2022	SELL	$62.2 - $84.4 $48,951 - $66,422	-787 Reduced 12.88%	5,321 $386,000
Q4 2021 Feb 09, 2022	BUY	$73.71 - $87.86 $1,547 - $1,845	21 Added 0.34%	6,108 $514,000
Q3 2021 Nov 04, 2021	SELL	$77.92 - $102.4 $20,259 - $26,624	-260 Reduced 4.1%	6,087 $549,000
Q2 2021 Aug 12, 2021	BUY	$92.19 - $115.71 $31,344 - $39,341	340 Added 5.66%	6,347 $605,000
Q1 2021 May 10, 2021	BUY	$106.9 - $167.73 $196,696 - $308,623	1,840 Added 44.16%	6,007 $684,000
Q4 2020 Feb 16, 2021	SELL	$84.4 - $177.39 $57,476 - $120,802	-681 Reduced 14.05%	4,167 $577,000
Q2 2020 Aug 10, 2020	SELL	$46.91 - $78.22 $3,846 - $6,414	-82 Reduced 1.66%	4,848 $379,000
Q1 2020 May 11, 2020	SELL	$33.8 - $62.9 $2,535 - $4,717	-75 Reduced 1.5%	4,930 $219,000
Q4 2019 Feb 13, 2020	SELL	$36.08 - $45.83 $4,870 - $6,187	-135 Reduced 2.63%	5,005 $214,000
Q3 2019 Nov 12, 2019	SELL	$42.5 - $63.11 $1,870 - $2,776	-44 Reduced 0.85%	5,140 $220,000
Q2 2019 Aug 12, 2019	SELL	$54.93 - $74.36 $6,426 - $8,700	-117 Reduced 2.21%	5,184 $329,000
Q4 2018 Feb 13, 2019	SELL	$38.89 - $77.3 $15,556 - $30,920	-400 Reduced 7.02%	5,301 $230,000
Q3 2018 Nov 13, 2018	BUY	$71.81 - $90.15 $409,388 - $513,945	5,701 New	5,701 $435,000

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.13B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.

Account

Shell Asset Management CO Ultragenyx Pharmaceutical Inc. Transaction History